Skip to main content
logo
GFC Life Science Co., Ltd (KOSDAQ:388610)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,530.00
-50.00 (-0.90%)
At close: Aug 24, 2026

GFC Life Science Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2021FY 2020FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '21 Dec '20 Dec '19
Revenue
19,23717,71516,80513,73713,32411,908
Revenue Growth
12.29%5.42%22.33%3.09%11.89%37.21%
Gross Profit
9,6148,5107,8776,4535,9273,884
Operating Income
841.08386.261,7051,379-7.37-757.9
Net Income
1,076555.43-5,9471,617-2,863448.7
Earnings Per Share
204.42115.31-1872.001560.00-2762.00433.00
EPS Growth
-77.71%-----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2021FY 2020FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '21 Dec '20 Dec '19
Cash & Investments
6,8517,7681,5381,210635.431,506
Total Debt
9,7177,5227,0227,42610,3008,456
Net Cash (Debt)
-2,866245.42-5,484-6,216-9,665-6,950
Net Cash Growth
------
Net Cash Per Share
-544.7950.95-1726.30-5996.61-9325.18-6707.09

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2021FY 2020FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '21 Dec '20 Dec '19
Operating Cash Flow
2,1781,3672,967941.21659.42-410.42
Capital Expenditures
-9,092-7,712-3,003-584.07-2,593-3,597
Free Cash Flow
-6,914-6,345-35.83357.14-1,934-4,007
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2021FY 2020FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '21 Dec '20 Dec '19
Gross Margin
49.98%48.04%46.88%46.98%44.49%32.62%
Operating Margin
4.37%2.18%10.14%10.04%-0.06%-6.36%
Pretax Margin
3.65%0.56%-34.12%12.07%-18.07%3.94%
Profit Margin
5.59%3.14%-35.39%11.77%-21.48%3.77%
FCF Margin
-35.94%-35.82%-0.21%2.60%-14.51%-33.65%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2021FY 2020FY 2019
Period EndingAug '26 Dec '25 Dec '24 Dec '21 Dec '20 Dec '19
PE Ratio
27.05134.31----
PS Ratio
1.514.213.80---